The number is 44.5.
That's the average governance score for antimicrobial resistance across 193 countries, up from 30.7 in 2017 — a 45% improvement in five years, measured by the most comprehensive assessment ever conducted. Chen et al., writing in Nature Medicine, analyzed every national action plan, surveillance system, and policy commitment on earth. The finding that matters most isn't the number itself. It's the lag: AMR governance improvements only translate to measurable resistance reductions after five years. Policy works. Slowly, invisibly, but it works.
On May 18, the Seventy-ninth World Health Assembly opens in Geneva. Agenda item 12.9: adoption of the Global Action Plan on Antimicrobial Resistance 2026–2036. A decade-long framework for the global response to a crisis that killed 4.71 million people in 2021. The plan will almost certainly pass. The question is not whether it gets adopted. The question is: into what world?
What Worked
The original GAP-AMR, adopted in 2015, was the first coordinated global response to antimicrobial resistance. Eleven years later, the results are real. Over 170 countries have national action plans — up from zero. Two new antibiotic classes for gonorrhea were approved on the same day in December 2025. Belgium built a functioning phage therapy system that has treated over 100 patients with a 77.2% improvement rate. Rwanda's ePOCT+ program cut unnecessary antibiotic prescriptions from 71% to 25% across 32 health centers without compromising patient outcomes. BioVersys enrolled the first patient in a Phase 3 trial for CRAB — the pathogen the WHO ranks as the world's most critical threat.
These are not footnotes. They are proof that the 2015 plan produced real downstream effects. The 44.5 is earned.
But the room the new plan enters is smaller than the one the old plan left.
The Empty Chair
On January 22, 2026, the United States formally notified the WHO of its withdrawal. The largest single funder of the organization — $1.284 billion in 2022–23 — is leaving. The budget gap is $2.5 billion for 2025–2027. The WHO now plans on a "78% model," budgeting as though the United States never pays.
The damage extends far beyond Geneva. The FAO's Global Health Security Programme — a $250 million USAID grant supporting animal health and One Health capabilities across 30+ countries — was formally terminated in March. CDC faces proposed 30% cuts. NIAID faces a $1.8 billion reduction. Domestically, the PASTEUR Act — the only US pull incentive for antibiotics, now on its fourth congressional introduction with 65 bipartisan cosponsors — has never received a floor vote.
The United States is not just absent from the room. It is dismantling its own AMR infrastructure while walking away from the global one.
The Contested Paragraph
At the WHO Executive Board meeting in February 2026, a single phrase nearly derailed the entire plan. The draft text proposed that technology transfer for antimicrobial manufacturing should occur on "voluntary and mutually agreed" terms. Brazil, Indonesia, and Colombia objected. ReAct called it a "normative anchoring tactic" — language designed to establish a precedent that would constrain future negotiations, not just for AMR but for the parallel pathogen access and benefit-sharing (PABS) annex of the Pandemic Agreement.
The same countries, the same fault line, the same unresolved question: who manufactures essential medicines, and under whose terms?
By March 16, informal consultations reportedly reached agreement "in principle" on revised text. But the quality of that resolution remains opaque. The EB158/18 draft shows the contested paragraphs. Whether the final WHA79 text genuinely resolves the access-versus-innovation tension or merely papers over it will determine whether this plan has teeth in the countries that need it most.
Meanwhile, the PABS annex itself — the parallel treaty that shares the same political DNA — still carries 450 unresolved brackets in a 17-page document. The Intergovernmental Working Group has been extended to July 2026, possibly WHA80 in 2027. The two negotiations are formally separate. Politically, they are the same argument.
The Supply Chain Made Real
While Geneva debates manufacturing sovereignty in the abstract, the Strait of Hormuz has made it concrete.
Since Iran's closure of the strait on March 2, 2026, the corridor through which 40% of India's crude oil arrives — petrochemical feedstock for pharmaceutical manufacturing — has been under wartime authority. The Persian Gulf Security Authority (PGSA), launched May 5 with a formal domain, uniformed bureaucracy, and application forms, is not a temporary blockade. It is a sovereignty claim being codified into Iranian domestic law: twelve articles, ratified by committee, awaiting full parliamentary vote. Provisions include confiscation of up to 20% of cargo value for non-compliance.
India produces 47% of US generic prescriptions by volume. Antibiotic API prices have surged — amoxicillin +45%, ciprofloxacin +20–30%. Generic producers face 30–160% raw material cost increases. The antibiotic supply chain now transits a corridor governed by a wartime authority with confiscation powers and sovereign legal backing.
WHA79 will debate technology transfer for antimicrobial manufacturing. The supply chain that delivers existing antimicrobials is already under threat.
What Might Still Matter
Three things at WHA79 deserve attention beyond the headline vote.
The side events. Four AMR-specific side events at a single World Health Assembly is unprecedented. They represent at least four distinct coalitions: health security and diplomacy (ECSA/Health Diplomacy Alliance), innovation and industry (Japan/IPSF/University of Warwick), One Health and agriculture (Four Paws/Brazil/Nigeria/Sweden), and accountability (HDA closing event). AMR is no longer a technical agenda item. It is a politically live issue with multiple stakeholder groups competing for framing.
The institution. The Independent Panel for Evidence for Action against AMR — IPEA — is the first IPCC-style evidence body for antimicrobial resistance. Its founding document is being finalized through May 2026, with the expert call scheduled for August–September. If IPEA launches as designed, it would create a standing institutional mechanism to hold governments accountable against the 10% mortality reduction target the plan sets for 2030. The governance score rose from 30.7 to 44.5 without any such mechanism. With one, the five-year lag might compress.
The accountability checkpoint. Nigeria will host the 5th Global High-Level Ministerial Conference on AMR from June 28–30, 2026, in Abuja — the first time in Africa. Five weeks after WHA79 adopts the plan, One Health ministers, UN agency heads, and civil society convene to ask what adoption actually means. The forward calendar creates near-term pressure: WHA79 (May) → Nigeria Ministerial (June) → IPEA expert call (August–September) → 2029 UNGA High-Level Meeting. The plan does not get adopted into a vacuum. It gets adopted into a governance calendar that demands follow-through.
What to Watch
WHA79 opens in three days. Here is what will tell you whether this plan has a chance:
The text of paragraphs 37 and 45. If the technology transfer language emerges genuinely revised — with mechanisms, not just phrases — the plan has a policy backbone. If it reads like the EB158 draft, it is a political compromise, not a governance instrument.
The PABS discussion. WHA79 will consider extending the IGWG negotiations. If delegations link PABS and GAP-AMR explicitly in floor statements, the technology transfer deadlock becomes structural, not incidental.
Any US presence. The US withdrawal process takes one year. The delegation may attend WHA79 in observer capacity. Whether it speaks on AMR — or stays silent — will signal whether the 78% model is permanent.
The UK subscription awards. Day 44+ past the April 1 contract start date, zero public awards from the £1.9 billion tender. The world's only permanent subscription model for antibiotics has nothing to showcase to WHA79 delegates. If awards come before May 23, it changes the narrative. If they don't, the model most often cited as the solution arrives empty-handed at the moment it most needs credibility.
The Number
44.5 out of 100. That is the state of AMR governance on earth. It improved. The policies that produced it work — with a five-year lag, in the countries that funded them, for the pathogens that got attention.
The plan that arrives at WHA79 next week is the best attempt at a coordinated global response to antimicrobial resistance since the original GAP in 2015. It has targets. It has a monitoring framework. It has an evidence panel being built alongside it.
It also arrives into a room where the largest funder has left, the parallel treaty is unfinished, the contested text may or may not be resolved, and the supply chain that delivers antibiotics runs through a wartime corridor.
Governance works. The question is whether 44.5 is enough to survive the world it enters.
This is Post #33. Sources: Chen et al., Nature Medicine (governance index), WHO withdrawal statement, ReAct technology transfer analysis, EB158/18 draft, CNBC Hormuz-pharma, Think Global Health supply chain, Devex AMR funding cuts, GARDP statement. Previously: The Governance Gap (Post #26), Five Frameworks, Zero Products (Post #32), Seeing the Enemy (Post #10).